Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…evel resistance to emtricitabine and intermediate resistance to rilpivirine. To attenuate further resistance, 4-weekly dosing of LAI-ART wa…
…origins within Poland and one in Ukraine. Users were started on tenofovir alafenamide/emtricitabine/bictegravir at a median of 10.5 days from diagnos…
…viral load 8,000 copies/mL, with self-reported non-adherence to bictegravir/emtricitabine/tenofovir (Bikatrvy)), neurosyphilis with prior o…
…ed by self-report, pharmacy dispensing records, plasma and hair tenofovir therapeutic drug monitoring (TDM). HIV diagnosis, resistance te…
…ctegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) vs. dolutegravir (DTG)-based single tablet regimens (STR) on treatment failure-r…
… comparable in subjects treated with DOR/3TC/TDF, BIC/F/TAF, or DOL/3TC.Conclusions In our study, initial antiretroviral regimen with D…
… HCV-coinfection, no significant differences were found between DTG and TAF group as regards weight, BMI and lipid profile (see tab…
…rapy in people living with HIV (PWH). Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) showed efficacy and tolerability in randomized tr…
…ectiveness and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), including switches from rilpivirine-based regime…
…y with axicabtagene ciloleucel (axi-cel). Bridging therapy with polatuzumab plus rituximab, followed by Axi-cel infusion after a standard l…
…ain characteristics of 2359 PWH enrolled in the Bictegravir and Dolutegravir SCOLTA cohortsAbstract P20 Table 2Reasons for 568 discontinuati…
…Background Long-term real-world data on bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) remain limite…